Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2015

View Archived Issues

Autologous human bone marrow-derived mononuclear stem cells used for diabetic critical limb ischemia

MedImmune characterizes dual GLP-1/glucagon agonist for obesity

Galderma discloses new preclinical models for neurogenic skin disorders

Evofem seeks U.S. approval of Amphora as contraceptive

Innate Pharma receives initial payment from AstraZeneca under IPH-2201 agreement

First-in-human study testing Oncoceutics' ONC-201

Progenics Pharmaceuticals to conduct phase III trial of 1404

Allergan enters into licensing agreement with Merck & Co. for CGRP migraine program

Dyax's DX-2930 receives FDA breakthrough therapy designation

FDA approves Entresto to reduce risk of cardiovascular death and heart failure hospitalization

Prima Biomed receives positive scientific advice from the EMA for IMP-321

Trophogen awarded second year of phase II SBIR grant

Roche divulges BACE1 inhibitors

Esteve reports sigma1 and mu-opioid receptor ligands

Sanofi patents AMPK activators

GlaxoSmithKline discloses KMO inhibitors

AbbVie develops BRD4 inhibitors

Incyte and Vanderbilt University Medical Center form oncology research collaboration

Allergan to acquire ocular device developer Oculeve

Cortactin identified as biomarker, possible therapeutic target in CLL

DSMB recommends continuation of Genticel's phase II trial of ProCervix

Hetlioz approved in the E.U. for non-24-hour sleep-wake disorder in totally blind adults

GNI initiates Chinese pilot study of Etuary for radiation-induced pneumonitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...